JHOP - December 2015 Vol 5, No 4
Laura Beth Parsons, Kathy Edwards, PharmD, BCPS, BCOP, Andy Perez, PharmD, BCOP, Cathy Letton, Carolyn Bondarenka
There have been a multitude of advances in the treatment of metastatic melanoma in the past decade, including approval of newer targeted therapies that often are better tolerated than previously used chemotherapy and immunotherapies.
The current treatment landscape for patients with high-risk localized prostate cancer is predominantly confined to a combination of androgen-deprivation therapy (ADT) plus radiotherapy, which has been shown to improve survival over radiotherapy alone.
Results 1 - 4 of 4